Re-infection with #SARS-CoV-2 is associated with increased #antibody breadth and potency against diverse #sarbecovirus strains, https://etidiohnew.blogspot.com/2026/02/re-infection-with-sars-cov-2-is.html
Re-infection with #SARS-CoV-2 is associated with increased #antibody breadth and potency against diverse #sarbecovirus strains

A new preprint describes a natural bat sarbecovirus carrying an intact furin cleavage site. This demonstrates that polybasic furin cleavage site motifs can arise in situ in wild coronaviruses, undermining claims that the SARS-CoV-2 furin cleavage site is diagnostic of laboratory engineering. https://doi.org/10.1101/2025.10.24.684489
#virology #covid #sarbecovirus
A divergent betacoronavirus with a functional furin cleavage site in South American bats

Bats are natural reservoirs for a wide range of RNA viruses. Members of the genus Betacoronavirus , including Severe Acute Respiratory Syndrome virus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome virus (MERS-CoV), have attracted particular attention due to their recent zoonotic emergence. However, much of the known diversity of betacoronaviruses is based on data from Asia, Africa, and the Middle East, with limited genomic information available from the Americas. Herein, we report the complete genome of a novel bat betacoronavirus identified from a Pteronotus parnellii bat sampled in Brazil. Phylogenetic analysis revealed that this virus is sufficiently distinct from the five recognized Betacoronavirus subgenera to represent a new subgenus. Of note, the spike protein of this novel bat coronavirus possesses a functional furin cleavage site at the S1/S2 junction with a unique amino acid sequence motif (RDAR) that differs from that found in SARS-CoV-2 (RRAR) by only one amino acid. Comparative structural analysis identified other betacoronaviruses in bats with furin cleavage sites at the S1/S2 junction, suggesting that this region is a structurally permissive “hotspot” for cleavage site incorporation. Our study provides a broader understanding of the phylogenetic and functional diversity of bat coronaviruses as well as their zoonotic potential. ### Competing Interest Statement Y.K. has received unrelated grant support from Daiichi Sankyo Co., Ltd., Fujifilm Toyama Chemical Co., Ltd., Tauns Laboratories, Inc., Shionogi & Co. Ltd., Otsuka Pharmaceutical Co., Ltd., KM Biologics Co. Ltd., Kyoritsu Seiyaku Corporation, Shinya Corporation and Fuji Rebio, Inc. Y.K. is a co-founder of FluGen. The other authors do not have any competing interests. KAKENHI Grants-in-Aid for Scientific Research on Innovative Areas, 16H06429, 16K21723, 16H06434 KAKENHI Grant-in-Aid for Scientific Research (B), JP22H02521 KAKENHI Grant-in-Aid for Early-Career Scientists, 25K18814, 22K15469 KAKENHI Grant-in-Aid for JSPS Fellows, 21J01036 AMED Research Program on Emerging and Re-emerging Infectious Diseases, JP19fk0108113, JP19fk018113 AMED, JP223fa627002, JP22am0401030, JP23fk0108659 AMED Advanced Research and Development Programs for Medical Innovation (AMED-CREST), 22gm1610010h0001 Takeda Science Foundation, https://ror.org/02y123g31 RIKAKEN HOLDINGS CO. Young Researcher Support Grant-in-aid National Health and Medical Research Council (Australia) Investigator grant, GNT2017197

bioRxiv
#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters #spike dynamics and enhances #ACE2 binding

Broadly #Sarbecovirus-Neutralizing #Antibodies Induced by Ancestral #SARS-CoV-2 #Infection

#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding, https://etidiohnew.blogspot.com/2025/04/bat-sarbecovirus-wiv1-cov-bears.html
#Bat #sarbecovirus WIV1-CoV bears an adaptive #mutation that alters spike dynamics and enhances #ACE2 binding

A trivalent #mucosal #vaccine encoding phylogenetically inferred ancestral #RBD #sequences confers pan- #Sarbecovirus #protection in mice https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(24)00403-7?rss=yes

Case et al. use ancestral phylogenetic reconstructions of Sarbecovirus sequences to generate a pan-Sarbecovirus vaccine. In mice, vaccine confers protection vs all tested Sarbecoviruses, including #SARS-CoV, multiple SARS-CoV-2 #variants, & pre-emergent Sarbecovirus strains.

#Coronavirus Disease Research #References (by AMEDEO, December 7 ’24)

  • VASSILOPOULOS S, Mylonakis E
    After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
    Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
    PubMed         Abstract available

    Antiviral Res

  • SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al
    Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine.
    Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046.
    PubMed         Abstract available

    Br J Anaesth

  • SPARLING JL, Chitilian HV, Korn E, Alfille PH, et al
    Induction of anaesthesia and airway management in patients with severe tracheal stenosis: a single-centre retrospective study.
    Br J Anaesth. 2024 Dec 4:S0007-0912(24)00667-6. doi: 10.1016/j.bja.2024.
    PubMed        

    Emerg Infect Dis

  • HASSAN AM, Muhlemann B, Al-Subhi TL, Rodon J, et al
    Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024.
    Emerg Infect Dis. 2024;31.
    PubMed         Abstract available

    Infect Control Hosp Epidemiol

  • KIM T, Moehring RW, Turner NA, Ashley ED, et al
    Long-term trends in the incidence of hospital-acquired carbapenem-resistant Enterobacterales and antimicrobial utilization in a network of community hospitals in the Southeastern United States from 2013 to 2023.
    Infect Control Hosp Epidemiol. 2024 Dec 3:1-7. doi: 10.1017/ice.2024.
    PubMed         Abstract available
  • USIAK S, Aslam A, Yan J, Madhavappallil J, et al
    Utility of post-admission SARS-CoV-2 serial testing in hospitalized patients with cancer.
    Infect Control Hosp Epidemiol. 2024 Dec 3:1-3. doi: 10.1017/ice.2024.
    PubMed         Abstract available
  • PASSARETTI CL, Bischoff W, Chan J, Diekema DJ, et al
    Respiratory equality: let’s stop playing favorites with COVID-19 in the healthcare setting.
    Infect Control Hosp Epidemiol. 2024 Dec 4:1-2. doi: 10.1017/ice.2024.
    PubMed        

    Int J Infect Dis

  • IP B, Pan S, Yao A, Lau L, et al
    COVID-19 vaccination and cerebral small vessel disease progression – A prospective cohort study.
    Int J Infect Dis. 2024 Dec 3:107324. doi: 10.1016/j.ijid.2024.107324.
    PubMed         Abstract available

    J Infect

  • PENG Y, Shen H, Zhang Y, Zeng S, et al
    A comprehensive pan-cancer analysis of SARS-CoV-2-related cancer malignancy: COVID-19 infection shapes a dynamic immune microenvironment and affects the prognosis.
    J Infect. 2024 Nov 30:106364. doi: 10.1016/j.jinf.2024.106364.
    PubMed        

    J Med Virol

  • ZWYGART AC, Medaglia C, Zhu Y, Bart Tarbet E, et al
    Development of Broad-Spectrum beta-Cyclodextrins-Based Nanomaterials Against Influenza Viruses.
    J Med Virol. 2024;96:e70101.
    PubMed         Abstract available
  • STICH M, Magalhaes VG, Burger F, Garbade SF, et al
    Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.
    J Med Virol. 2024;96:e70098.
    PubMed         Abstract available
  • MAIMAITI M, Kong L, Yu Q, Wang Z, et al
    Analytical Performance of a Novel Nanopore Sequencing for SARS-CoV-2 Genomic Surveillance.
    J Med Virol. 2024;96:e70108.
    PubMed         Abstract available

    J Virol

  • ZUO F, Cao Y, Sun R, Wang Q, et al
    Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants.
    J Virol. 2024 Dec 4:e0174024. doi: 10.1128/jvi.01740.
    PubMed        
  • ZHANG Y, Zhang N, Zhang Y, Li Y, et al
    Potassium molybdate blocks APN-dependent coronavirus entry by degrading receptor via PIK3C3-mediated autophagy.
    J Virol. 2024 Dec 6:e0144924. doi: 10.1128/jvi.01449.
    PubMed         Abstract available

    JAMA

  • ANDERER S
    CDC Recommends Second COVID-19 Vaccine Dose for Older Adults.
    JAMA. 2024 Dec 6. doi: 10.1001/jama.2024.24258.
    PubMed        

    Nature

  • KUDIABOR H
    Virtual lab powered by ‘AI scientists’ super-charges biomedical research.
    Nature. 2024 Dec 4. doi: 10.1038/d41586-024-01684.
    PubMed        

    Science

  • KAISER J
    Trump picks an ‘outsider’ and NIH critic to lead agency.
    Science. 2024;386:1080-1081.
    PubMed         Abstract available
  • #betacoronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2 #science

    After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y - PubMed

    Taylor K, Eastwood S, Walker V, et al. <b>Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people.</b> Lancet Diabetes Endocrinol. 2024;12:558-568. 39054034.

    PubMed

    #Coronavirus Disease Research #References (by AMEDEO, December 1 ’24)

  • MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
    Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
    Antiviral Res. 2024;232:106038.
    PubMed         Abstract available
  • AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
    Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
    Antiviral Res. 2024;232:106041.
    PubMed         Abstract available
  • GENG X, Zhu Y, Gao Y, Chong H, et al
    Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy.
    Antiviral Res. 2024 Nov 23:106042. doi: 10.1016/j.antiviral.2024.106042.
    PubMed         Abstract available

    BMJ

  • ZERAATKAR D, Ling M, Kirsh S, Jassal T, et al
    Interventions for the management of long covid (post-covid condition): living systematic review.
    BMJ. 2024;387:e081318.
    PubMed         Abstract available

    Clin Infect Dis

  • TOWNSEND JP, Hassler HB, Dornburg A
    Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection.
    Clin Infect Dis. 2024 Nov 26:ciae559. doi: 10.1093.
    PubMed         Abstract available
  • FAUCI AS, Folkers GK
    HIV/AIDS and COVID-19: Shared Lessons from Two Pandemics.
    Clin Infect Dis. 2024 Nov 27:ciae585. doi: 10.1093.
    PubMed         Abstract available
  • LEWIS NM, Harker EJ, Grant LB, Zhu Y, et al
    Benefit of early oseltamivir therapy for adults hospitalized with influenza A: an observational study.
    Clin Infect Dis. 2024 Nov 28:ciae584. doi: 10.1093.
    PubMed         Abstract available

    Infect Control Hosp Epidemiol

  • SANDS KE, Blanchard EJ, Hasse A, Korwek K, et al
    Risk factors for healthcare-associated infection among patients hospitalized with COVID-19 infection.
    Infect Control Hosp Epidemiol. 2024 Nov 25:1-2. doi: 10.1017/ice.2024.
    PubMed        

    Int J Infect Dis

  • CHUN HM, Osawe S, Adams-Dabban S, Favaloro J, et al
    SARS-CoV-2 Serologic Surveillance Among People Living with HIV in Nigeria, April 2022-January 2023.
    Int J Infect Dis. 2024 Nov 21:107309. doi: 10.1016/j.ijid.2024.107309.
    PubMed         Abstract available
  • YANG X, Zhang J, Liu Z, Chen S, et al
    Real-world effectiveness of COVID-19 vaccine in people with HIV compared with a matched HIV-negative cohort: a test-negative design.
    Int J Infect Dis. 2024 Nov 22:107310. doi: 10.1016/j.ijid.2024.107310.
    PubMed         Abstract available
  • PETT SL
    Predictors of hospitalisation, death and incomplete/non-recovery from SARS-CoV-2 in an ambulatory global population.
    Int J Infect Dis. 2024 Nov 26:107285. doi: 10.1016/j.ijid.2024.107285.
    PubMed         Abstract available

    J Infect

  • JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    PubMed         Abstract available

    J Med Virol

  • SIDDIQUE AI, Sarmah N, Bali NK, Nausch N, et al
    Differential Gene Expression and Transcriptomics Reveal High M-Gene Expression in JN.1 and KP.1/2 Omicron Sub-Variants of SARS-CoV-2: Implications for Developing More Sensitive Diagnostic Tests.
    J Med Virol. 2024;96:e70074.
    PubMed         Abstract available
  • USHIJIMA H, Pham NTK, Nishimura S, Kobayashi M, et al
    Human Astrovirus Infection and Outbreaks in Japanese Children Before and After the Emergence of COVID-19 Pandemic.
    J Med Virol. 2024;96:e70078.
    PubMed         Abstract available
  • CHEN J, Zhang Y, Zhang B, Wang Z, et al
    In Vitro Characterization of Inhibition Function of Calcifediol to the Protease Activity of SARS-COV-2 PLpro.
    J Med Virol. 2024;96:e70085.
    PubMed         Abstract available
  • TIAN W, Han Z, Shi D, Wang H, et al
    Indeterminate Result of Interferon-gamma Release Assay-A Risk Factor of Mortality for COVID-19 and Non-COVID-19 Respiratory Infections.
    J Med Virol. 2024;96:e70058.
    PubMed         Abstract available
  • GRANINGER M, Endmayr V, Kuhner LM, Berger SM, et al
    Association Between NK Cell Genetic Variants and the Development of Long COVID Associated- and Prepandemic Small Fiber Neuropathy.
    J Med Virol. 2024;96:e70091.
    PubMed         Abstract available
  • WANG J, Ni S, Chen Q, Wang C, et al
    Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity.
    J Med Virol. 2024;96:e70073.
    PubMed         Abstract available

    J Virol

  • KAKIZAKI M, Hashimoto R, Nagata N, Yamamoto T, et al
    The respective roles of TMPRSS2 and cathepsins for SARS-CoV-2 infection in human respiratory organoids.
    J Virol. 2024 Nov 27:e0185324. doi: 10.1128/jvi.01853.
    PubMed         Abstract available

    Lancet

  • FERRANTE M, D’Haens G, Jairath V, Danese S, et al
    Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
    Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762.
    PubMed         Abstract available
  • DWYER-LINDGREN L, Baumann MM, Li Z, Kelly YO, et al
    Ten Americas: a systematic analysis of life expectancy disparities in the USA.
    Lancet. 2024 Nov 19:S0140-6736(24)01495-8. doi: 10.1016/S0140-6736(24)01495.
    PubMed         Abstract available

    Lancet Infect Dis

  • GOSWAMI J, Cardona JF, Hsu DC, Simorellis AK, et al
    Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Lancet Infect Dis. 2024 Nov 25:S1473-3099(24)00589.
    PubMed         Abstract available
  • LIU J, Yu Y, Jian F, Yang S, et al
    Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.
    Lancet Infect Dis. 2024 Nov 22:S1473-3099(24)00738.
    PubMed        

    Science

  • LIBBY P
    Endothelial inflammation in COVID-19.
    Science. 2024;386:972-973.
    PubMed         Abstract available
  • COHEN J
    Children are left behind in Congo’s mpox vaccination drive.
    Science. 2024;386:954.
    PubMed         Abstract available

    Travel Med Infect Dis

  • KHAN AA, Balkhi BS, Alamri FA, Alsaleh GS, et al
    Vaccinations for Hajj: Enhancing health and global health security.
    Travel Med Infect Dis. 2024;63:102784.
    PubMed         Abstract available
  • WANG J, Ge L, Zhou K, Jiang Y, et al
    Effect of omicron infection on maternal and neonatal delivery outcomes: A retrospective cohort study.
    Travel Med Infect Dis. 2024;62:102759.
    PubMed         Abstract available
  • #abstract #betacoronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #vaccine

    Biological characterization of AB-343, a novel and potent SARS-CoV-2 Mpro inhibitor with pan-coronavirus activity - PubMed

    Since the SARS-CoV-2 outbreak, there have been ongoing efforts to identify antiviral molecules with broad coronavirus activity to combat COVID-19. SARS-CoV-2's main protease (M<sup>pro</sup>) is responsible for processing the viral polypeptide into non-structural proteins essential for replication. …

    PubMed

    #Recombination across distant #coronavirid #species and #genera is a rare #event with distinct #genomic features

    Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01100-24?af=R

    ABSTRACT
    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus) has caused millions of deaths, prompting a need for better understanding of coronavirid emergence and spillover to humans. As an evaluation of how some features of SARS-CoV-2, unique among sarbecoviruses, may have been acquired from related viruses, we conducted phylogenetic and recombination analyses to compare the frequency of recombination among coronavirids across vs within genera, subgenera, and species. Among known betacoronaviruses, we identified 199 (183 intraspecies, 16 interspecies, but no intersubgenera) recombination events. Phylogenetic analyses revealed that the ancestry of interspecies events was limited and less prone to affect 5′ regions of coronavirid genome open reading frame 1 (ORF1) than intraspecies events. On the contrary, interspecies events were significantly more prone to impact the 3′ end (ORF6–ORF8 and the nucleocapsid protein [N] ORF), suggesting the existence of region-specific constraints on recombination. This work substantiated that recombination among betacoronaviruses is limited by the genome similarity between their parental viruses. We conclude that SARS-CoV-2 likely acquired unique features through recombination with closely related circulating sarbecoviruses (most likely from the same species) that co-existed geographically.

    ____

    #abstract #betacoronavirus #biology #coronavirus #evolution #genetics #health #research #sarbecovirus #sarsCov2 #science

    #Coronavirus Disease Research #References (by AMEDEO, Nov. 16 ’24)

  • AYYALA-SOMAYAJULA D, Dodge JL, Leventhal AM, Terrault NA, et al
    Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study.
    Ann Intern Med. 2024 Nov 12. doi: 10.7326/ANNALS-24-02157.
    PubMed        

    Antiviral Res

  • SAMA B, Selisko B, Falcou C, Fattorini V, et al
    The effects of Remdesivir’s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase.
    Antiviral Res. 2024 Nov 5:106034. doi: 10.1016/j.antiviral.2024.106034.
    PubMed         Abstract available

    BMJ

  • GREENHALGH T, Misak C, Payne R, Swann N, et al
    Patient involvement in developing clinical guidelines.
    BMJ. 2024;387:q2433.
    PubMed        

    Br J Anaesth

  • ANGELOPOULOS N, Staines J, Chamberlin M, Bates S, et al
    A narrative review of personal protective equipment gowns: lessons from COVID-19.
    Br J Anaesth. 2024 Nov 7:S0007-0912(24)00567-1. doi: 10.1016/j.bja.2024.
    PubMed         Abstract available

    Clin Infect Dis

  • GRANT R, de Kraker MEA, Buetti N, Jackson H, et al
    In-hospital outcomes of healthcare-associated COVID-19 (Omicron) versus healthcare-associated influenza: a retrospective, nationwide cohort study in Switzerland.
    Clin Infect Dis. 2024 Nov 13:ciae558. doi: 10.1093.
    PubMed         Abstract available
  • HAMMOND J, Leister-Tebbe H, Gardner A, Abreu P, et al
    Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
    Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093.
    PubMed         Abstract available

    Emerg Infect Dis

  • CREPPAGE KE, Gallaway MS, Russell DA, Early JM, et al
    Global Emerging Infections Surveillance Program Contributions to Pandemic Preparedness and Response.
    Emerg Infect Dis. 2024;30:9-12.
    PubMed         Abstract available
  • MORTON LC, Rahman N, Bishop-Lilly KA
    Next-Generation Sequencing and Bioinformatics Consortium Approach to Genomic Surveillance.
    Emerg Infect Dis. 2024;30:13-18.
    PubMed         Abstract available
  • MUEHLEMAN D, Gruner B, Hogan V, Fanning P, et al
    Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.
    Emerg Infect Dis. 2024;30:53-61.
    PubMed         Abstract available
  • TINOCO YO, Osman TS, Ampuero JS, Gazo M, et al
    Respiratory Disease Surveillance in the Middle East and Latin America during the COVID-19 Pandemic, 2020-2022.
    Emerg Infect Dis. 2024;30:26-32.
    PubMed         Abstract available
  • ODUNDO EA, Kipkirui EC, Koech MC, Kirui MC, et al
    Azithromycin Resistance Patterns in Escherichia coli and Shigella before and after COVID-19, Kenya.
    Emerg Infect Dis. 2024;30:86-93.
    PubMed         Abstract available

    Int J Infect Dis

  • GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Corrigendum to “Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study” [Internation Journal of Infectious Diseases, volume 144 (2024) 107064].
    Int J Infect Dis. 2024;149:107278.
    PubMed        
  • LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Erratum to ‘Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study’.
    Int J Infect Dis. 2024;149:107286.
    PubMed        

    Intensive Care Med

  • KESECIOGLU J, Rusinova K, Alampi D, Arabi YM, et al
    European Society of Intensive Care Medicine guidelines on end of life and palliative care in the intensive care unit.
    Intensive Care Med. 2024 Oct 3. doi: 10.1007/s00134-024-07579.
    PubMed         Abstract available
  • OLMOS M, Esperatti M, Fuentes N, Miranda Tirado A, et al
    Early physiologic changes after awake prone positioning predict clinical outcomes in patients with acute hypoxemic respiratory failure.
    Intensive Care Med. 2024 Nov 14. doi: 10.1007/s00134-024-07690.
    PubMed         Abstract available

    J Infect

  • DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    PubMed         Abstract available
  • HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    PubMed         Abstract available
  • FOONG KS
    Corrigendum to “The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19” [J Infe
    J Infect. 2024;89:106343.
    PubMed        

    J Med Virol

  • USTIUZHANINA MO, Boyko AA, Vavilova JD, Siniavin AE, et al
    The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression.
    J Med Virol. 2024;96:e70057.
    PubMed         Abstract available
  • ZHANG C, Wang M, Sun S, Yi M, et al
    Impact of COVID-19 on the Prevalence and Drug Resistance of Bacteria Isolated From Bacterial Meningitis Cerebrospinal Fluid in Shandong Province: A Multicenter Retrospective Study.
    J Med Virol. 2024;96:e70063.
    PubMed         Abstract available
  • ESPI M, Charmetant X, Benotmane I, Lefsihane K, et al
    Memory B Cells Provide Long-Term Protection to Vaccinated Kidney Transplant Recipients Against SARS-CoV-2 Variants.
    J Med Virol. 2024;96:e70037.
    PubMed         Abstract available
  • FACCO JV, Addas-Carvalho M, Duarte ADSS, Zangirolami AB, et al
    HLA-B*15 Is Associated With SARS-CoV-2 Infection in a Brazilian Population.
    J Med Virol. 2024;96:e70028.
    PubMed         Abstract available
  • WANG N, Lin Q, Fan H, Wang Y, et al
    BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.
    J Med Virol. 2024;96:e70036.
    PubMed         Abstract available
  • YE C, Tian Y, Huo D, Zhang T, et al
    Changes in Epidemics of Respiratory Viral Infections Resulted From the COVID-19 Pandemic in Shanghai.
    J Med Virol. 2024;96:e70034.
    PubMed         Abstract available

    J Virol

  • CHEN Y, Ou X, Li P, Zan F, et al
    Identification of the critical residues of TMPRSS2 for entry and host range of human coronavirus HKU1.
    J Virol. 2024 Nov 11:e0158724. doi: 10.1128/jvi.01587.
    PubMed         Abstract available
  • STEIGMANN JC, Zhou X, Suttenberg LN, Salman I, et al
    Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.
    J Virol. 2024 Nov 7:e0123824. doi: 10.1128/jvi.01238.
    PubMed         Abstract available

    JAMA

  • ANDERER S
    FDA Authorizes First At-Home COVID-19 and Flu Combo Test.
    JAMA. 2024 Nov 8. doi: 10.1001/jama.2024.22561.
    PubMed        

    Lancet

  • DWYER-LINDGREN L, Kendrick P, Baumann MM, Li Z, et al
    Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008-21: an analysis using the Human Development Index.
    Lancet. 2024 Nov 6:S0140-6736(24)01757-4. doi: 10.1016/S0140-6736(24)01757.
    PubMed         Abstract available
  • ALWAN NA, Al-Aly Z
    Learning from long COVID: conceptualising action to tackle infection-associated non-communicable diseases.
    Lancet. 2024 Nov 6:S0140-6736(24)02256-6. doi: 10.1016/S0140-6736(24)02256.
    PubMed        
  • Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed         Abstract available

    Lancet Infect Dis

  • ARORA P, Happle C, Kempf A, Nehlmeier I, et al
    Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
    Lancet Infect Dis. 2024 Nov 7:S1473-3099(24)00688.
    PubMed        
  • KAKU Y, Okumura K, Kawakubo S, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 XEC variant.
    Lancet Infect Dis. 2024 Nov 6:S1473-3099(24)00731.
    PubMed        

    MMWR Morb Mortal Wkly Rep

  • LEFFERTS B, Bressler S, Keck JW, Desnoyers C, et al
    Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children – Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1015-1021.
    PubMed         Abstract available
  • MINTA AA, Ferrari M, Antoni S, Lambert B, et al
    Progress Toward Measles Elimination – Worldwide, 2000-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1036-1042.
    PubMed         Abstract available

    N Engl J Med

  • SCHMIDT P, Li Y, Popejoy M
    Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19.
    N Engl J Med. 2024;391:1860-1862.
    PubMed        
  • WANG Q, Guo Y, Ho J, Ho DD, et al
    Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages.
    N Engl J Med. 2024;391:1863-1864.
    PubMed        
  • JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed         Abstract available

    Nature

  • JIAN F, Wang J, Yisimayi A, Song W, et al
    Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
    Nature. 2024 Nov 7. doi: 10.1038/s41586-024-08315.
    PubMed         Abstract available
  • SOLIMAN A
    US trust in scientists plunged during the pandemic – but it’s starting to recover.
    Nature. 2024 Nov 14. doi: 10.1038/d41586-024-03723.
    PubMed        

    Science

  • CHEN Z, Tsui JL, Gutierrez B, Busch Moreno S, et al
    COVID-19 pandemic interventions reshaped the global dispersal of seasonal influenza viruses.
    Science. 2024;386:eadq3003.
    PubMed         Abstract available
  • ROHANI P, Bahl J
    Collateral effects of pandemic control.
    Science. 2024;386:620-621.
    PubMed         Abstract available
  • VOGEL G
    ‘America first’ could affect health worldwide.
    Science. 2024;386:715.
    PubMed         Abstract available
  • #abstract #betacoronavirus #covid #COVID19 #health #news #research #sarbecovirus #sarsCov2

    Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study - PubMed

    Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study

    PubMed